Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Measurable Residual Disease Predicts Real-World AML Relapse

2.

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

3.

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

4.

FDA Expands Approval of Osimertinib in Lung Cancer

5.

Effective Intralesional Melanoma Therapy May Involve Systemic Effects.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot